Source control review in clinical trials of anti-infective agents in complicated intra-abdominal infections

Clinical Infectious Diseases

Volumn 56, Issue 12, 2013, Pages 1765-1773

  Solomkin, Joseph S ^a   Ristagno, Ross L ^a   Das, Anita F ^b   Cone, John B ^c   Wilson, Samuel E ^d   Rotstein, Ori D ^e   Murphy, Brian S ^f   Severin, Kimberley S ^f   Bruss, Jon B ^f  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Axistat   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f Medpace ^*  (United States)

Author keywords

adjudication; intra abdominal infections; review board; source control

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; BIAPENEM; CEFALORIDINE; CEFAMANDOLE; CEFAZOLIN; CEFEPIME; CEFMETAZOLE; CEFOPERAZONE; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CILASTATIN; CIPROFLOXACIN; CLINAFLOXACIN; CLINDAMYCIN; DORIPENEM; ERTAPENEM; IMIPENEM; LATAMOXEF; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; TINIDAZOLE; TROVAFLOXACIN; UNINDEXED DRUG;

ABDOMINAL INFECTION; ANTIBIOTIC THERAPY; COMPLICATED INTRAABDOMINAL INFECTION; HUMAN; MEDLINE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURGICAL APPROACH; SYSTEMATIC REVIEW;

ADJUDICATION; INTRA-ABDOMINAL INFECTIONS; REVIEW BOARD; SOURCE CONTROL;

ANTI-INFECTIVE AGENTS; CLINICAL TRIALS AS TOPIC; CONSENSUS; HUMANS; INTRAABDOMINAL INFECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84878337468     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit128     Document Type: Review

References (14)

1. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37:997-1005.
2. Ohmann C, Yang Q, Hau T, Wacha H. Prognostic modeling in peritonitis. Peritonitis Study Group of the Surgical Infection Society Europe. Eur J Surg 1997; 163:53-60.
3. Wacha H, Hau T, Dittmer R, Ohmann C. Risk factors associated with intraabdominal infections: a prospective multicenter study. Peritonitis Study Group. Langenbecks Arch Surg 1999; 384:24-32.
4. Suding PN, Orrico RP, Johnson SB, Wilson SE. Concordance of interrater assessments of surgical methods to achieve source control of intra-abdominal infections. Am J Surg 2008; 196:70-3.
5. Solomkin JS, Reinhart HH, Dellinger EP, et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxa-cin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. Ann Surg 1996; 223:303-15.
6. Solomkin JS, Wilson SE, Christou NV, Rotstein OD, Dellinger EP, Bennion RS. Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intra-abdominal infections. Ann Surg 2001; 233:79-87.
7. Solomkin JS, Yellin AE, Rotstein OD, et al. Ertapenem versus piperacil-lin/tazobactam in the treatment of complicated intra-abdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg 2003; 2:235-45.
8. Namias N, Solomkin JS, Jensen EH, Tomassini JE, Abramson MA. Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults. Surg Inf 2007; 8:15-28.
9. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E, for the Tigecycline 301 and 306 Study Groups. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41:S354-66.
10. Center for Drug Evaluation and Research. Application Number 21-821. Medical review of tigecycline. 2005.
11. Center for Drug Evaluation and Research. Application Number 22-106. Medical review of doripenem. 2007.
12. Center for Drug Evaluation and Research. Application Number 22-106. Statistical review of doripenem. 2007.
13. Powers JH. Increasing the efficiency of clinical trials of antimicrobials: the scientific basis of substantial evidence of effectiveness of drugs. Clin Infect Dis 2007; 45(Suppl 2):S153-62.
14. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Bio-logics Evaluation and Research. Guidance for Industry: Non-Inferiority Clinical Trials, Rockville, MD; 2010.